| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Legend Biotech (NASDAQ:LEGN) will release its quarterly earnings report on Monday, 2025-08-11. Here's a brief overview for investors ahead of the announcement.
Analysts anticipate Legend Biotech to report an earnings per share (EPS) of $-0.21.
Anticipation surrounds Legend Biotech's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.
New investors should understand that while earnings performance is important, market reactions are often driven by guidance.
Last quarter the company beat EPS by $0.18, which was followed by a 10.55% drop in the share price the next day.
Here's a look at Legend Biotech's past performance and the resulting price change:
| Quarter | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|
| EPS Estimate | -0.25 | -0.33 | -0.42 | -0.38 |
| EPS Actual | -0.07 | -0.15 | -0.34 | -0.05 |
| Price Change % | -11.0% | 3.0% | -2.0% | -2.0% |
Shares of Legend Biotech were trading at $37.43 as of August 07. Over the last 52-week period, shares are down 34.4%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release.
To track all earnings releases for Legend Biotech visit their earnings calendar on our site.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: LEGN
